Guo Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guo Yu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Guo-Fu Li
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
12 shared publications Na Zhang
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
4 shared publications- De-Chuan Zhan
School of Artificial Intelligence, National Key Laboratory for Novel Software Technology, Nanjing University, Nanjing, China
3 shared publications Guangji Wang
State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University , No. 24 Tongjiaxiang, Gulou District, Nanjing 210009
3 shared publicationsLi-Rong Jiao
Clinical Medical College, Yangzhou University, Yangzhou, China
3 shared publicationsYichao Yu
Department of Pharmaceutics, University of Florida, Gainesville, Florida; Department of Biostatistics, University of Florida, Gainesville, Florida
3 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary–physicochemical analysis
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics, yet early translation is often hindered by the perceived coupling between antibacterial potency and mammalian toxicity. This assumption complicates prioritization: highly active candidates are frequently suspected to be hemolytic, while existing multi-task predictors rarely reveal where selectivity resides in sequence space. Here, we present Multifunctional AMP Learning Engine (MAPLE), an interpretable dual-stream framework for AMP identification and systematic category-specific functional profiling across 14 activity categories directly from peptide sequences. MAPLE combines protein language model embeddings with explicit physicochemical descriptors, enabling robust task-specific prediction under severe label imbalance. Across the benchmark dataset and a sequence-non-overlapping independent validation set, MAPLE achieves consistently well-balanced performance, including on low-prevalence but clinically relevant endpoints. Building on this predictive basis, we conduct systematic k-mer enrichment to map motif-level selectivity and show that potency–hemolysis coupling is motif-regime-dependent rather than universal. Motifs most strongly enriched for antibacterial activity exhibit reduced hemolytic overlap and occupy a physicochemical regime characterized by moderate cationicity, lower hydrophobicity, and higher amphipathicity. We further provide a proof-of-concept prioritization workflow leveraging antibacterial-selective motifs, with structural modeling yielding conformations consistent with amphipathic α-helices. Despite limitations of predominantly binary annotations and incomplete structural integration, MAPLE offers reproducible sequence-level hypotheses and prioritization principles to support the engineering of potent and safer AMPs.
- 4 May 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (3)
Open AccessMAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary–physicochemical analysis
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics, yet early translation is often hindered by the perceived coupling between antibacterial potency and mammalian toxicity. This assumption complicates prioritization: highly active candidates are frequently suspected to be hemolytic, while existing multi-task predictors rarely reveal where selectivity resides in sequence space. Here, we present Multifunctional AMP Learning Engine (MAPLE), an interpretable dual-stream framework for AMP identification and systematic category-specific functional profiling across 14 activity categories directly from peptide sequences. MAPLE combines protein language model embeddings with explicit physicochemical descriptors, enabling robust task-specific prediction under severe label imbalance. Across the benchmark dataset and a sequence-non-overlapping independent validation set, MAPLE achieves consistently well-balanced performance, including on low-prevalence but clinically relevant endpoints. Building on this predictive basis, we conduct systematic k-mer enrichment to map motif-level selectivity and show that potency–hemolysis coupling is motif-regime-dependent rather than universal. Motifs most strongly enriched for antibacterial activity exhibit reduced hemolytic overlap and occupy a physicochemical regime characterized by moderate cationicity, lower hydrophobicity, and higher amphipathicity. We further provide a proof-of-concept prioritization workflow leveraging antibacterial-selective motifs, with structural modeling yielding conformations consistent with amphipathic α-helices. Despite limitations of predominantly binary annotations and incomplete structural integration, MAPLE offers reproducible sequence-level hypotheses and prioritization principles to support the engineering of potent and safer AMPs.
- 27 November 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 253-263
Risk Factors for Drug‐Induced Severe Cutaneous Adverse Reactions: A Real‐World Pharmacovigilance Analysis
Drug‐induced severe cutaneous adverse reactions (SCARs) are rare but potentially life‐threatening drug‐induced hypersensitivity reactions. Current understanding of the drug risks associated with SCARs is limited, emphasizing the need for more research to identify and understand medications that may trigger these reactions. This study aimed to identify risk factors and suspect drugs associated with SCARs. Disproportionality analysis was conducted through the case–control design using the FDA Adverse Event Reporting System (FAERS) database of drug‐induced SCARs. The reporting odds ratios (ROR) were used to analyze reports of drug‐induced SCARs from January 1, 2004, to March 31, 2025. Least absolute shrinkage and selection operator (LASSO), and multivariable regression analyses were conducted to identify risk factors associated with SCARs. Bonferroni correction was applied to adjust for multiple comparisons. A total of 103 337 drug‐induced SCARs cases were identified. The median patient age was 57.00 years (IQR 37.00–70.00), with a nearly equal sex distribution (49.26% female, 40.57% male). Disproportionality analysis identified 415 drugs with positive signals for drug‐induced SCARs. Logistic regression identified older age, male sex, and 114 drugs as independent risk factors for drug‐induced SCARs, including amlodipine (adjusted ROR = 2.89), bisoprolol (adjusted ROR = 3.52), and losartan (adjusted ROR = 2.77). In the non‐Asian population, the strongest signals were observed for allopurinol (adjusted ROR = 98.52), cefotaxime (adjusted ROR = 68.52), and lamotrigine (adjusted ROR = 38.59), whereas apalutamide (adjusted ROR = 14.57), ipilimumab (adjusted ROR = 3.24), and acetylsalicylic acid (adjusted ROR = 2.85) were detected only in Asians. The median time to onset (TTO) of drug‐induced SCARs was 14 days (IQR 4–47). The Asian population had a significantly shorter TTO compared to the non‐Asian population ( p < 0.001). This study uses FAERS data to analyze risk factors for drug‐induced SCARs, emphasizing early identification and discontinuation of suspected drugs to enhance patient safety.
- 27 November 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (2) , 253-263
Risk Factors for Drug‐Induced Severe Cutaneous Adverse Reactions: A Real‐World Pharmacovigilance Analysis
Drug‐induced severe cutaneous adverse reactions (SCARs) are rare but potentially life‐threatening drug‐induced hypersensitivity reactions. Current understanding of the drug risks associated with SCARs is limited, emphasizing the need for more research to identify and understand medications that may trigger these reactions. This study aimed to identify risk factors and suspect drugs associated with SCARs. Disproportionality analysis was conducted through the case–control design using the FDA Adverse Event Reporting System (FAERS) database of drug‐induced SCARs. The reporting odds ratios (ROR) were used to analyze reports of drug‐induced SCARs from January 1, 2004, to March 31, 2025. Least absolute shrinkage and selection operator (LASSO), and multivariable regression analyses were conducted to identify risk factors associated with SCARs. Bonferroni correction was applied to adjust for multiple comparisons. A total of 103 337 drug‐induced SCARs cases were identified. The median patient age was 57.00 years (IQR 37.00–70.00), with a nearly equal sex distribution (49.26% female, 40.57% male). Disproportionality analysis identified 415 drugs with positive signals for drug‐induced SCARs. Logistic regression identified older age, male sex, and 114 drugs as independent risk factors for drug‐induced SCARs, including amlodipine (adjusted ROR = 2.89), bisoprolol (adjusted ROR = 3.52), and losartan (adjusted ROR = 2.77). In the non‐Asian population, the strongest signals were observed for allopurinol (adjusted ROR = 98.52), cefotaxime (adjusted ROR = 68.52), and lamotrigine (adjusted ROR = 38.59), whereas apalutamide (adjusted ROR = 14.57), ipilimumab (adjusted ROR = 3.24), and acetylsalicylic acid (adjusted ROR = 2.85) were detected only in Asians. The median time to onset (TTO) of drug‐induced SCARs was 14 days (IQR 4–47). The Asian population had a significantly shorter TTO compared to the non‐Asian population ( p < 0.001). This study uses FAERS data to analyze risk factors for drug‐induced SCARs, emphasizing early identification and discontinuation of suspected drugs to enhance patient safety.
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2753-2754
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2753-2754
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer
- Open Access
- 28 May 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 211, 107146
Applying exposure-response analysis to enhance Mycophenolate Mofetil dosing precision in pediatric patients with immune-mediated renal diseases by machine learning models
- 28 May 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 211, 107146
Open AccessApplying exposure-response analysis to enhance Mycophenolate Mofetil dosing precision in pediatric patients with immune-mediated renal diseases by machine learning models
- 13 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (7) , 873-882
Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have shown promising prospects as novel therapeutic agents in renal anemia, but their potential cardiovascular toxicities have raised widespread concern. This study aim to explore the cardiovascular toxicities associated with HIF-PHIs through real-world long-term safety data. A disproportionality analysis was employed by calculating the reporting odds ratios (ROR), information component (IC), and their 95% credibility intervals (CrI) in Japan Adverse Drug Event Report (JADER) database from 1 January 2020, to 30 September 2023. From Q1 2020 to Q3 2023, 253,599 adverse events (AEs) cases were extracted from the JADER database, including 4,015 cases related to HIF-PHIs and 1,537 (38.28%) cases of cardiovascular toxicities. Embolic and thrombotic events (ROR = 6.66, IC = 2.74), cardiac failure (ROR = 3.86, IC = 1.95), and ischemic heart disease (ROR = 3.37, IC = 1.75) indicated positive signals in HIF-PHIs. The median time to onset (TTO) of hypertension for HIF-PHIs was noted to be the earliest at 15.50 days. HIF-PHIs are related to multiple cardiovascular toxicities. Although disproportionality analysis is a hypothesis-driven method, improving the surveillance of these toxicities related to HIF-PHIs used in managing renal anemia is still crucial.
- 13 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 24 (7) , 873-882
Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have shown promising prospects as novel therapeutic agents in renal anemia, but their potential cardiovascular toxicities have raised widespread concern. This study aim to explore the cardiovascular toxicities associated with HIF-PHIs through real-world long-term safety data. A disproportionality analysis was employed by calculating the reporting odds ratios (ROR), information component (IC), and their 95% credibility intervals (CrI) in Japan Adverse Drug Event Report (JADER) database from 1 January 2020, to 30 September 2023. From Q1 2020 to Q3 2023, 253,599 adverse events (AEs) cases were extracted from the JADER database, including 4,015 cases related to HIF-PHIs and 1,537 (38.28%) cases of cardiovascular toxicities. Embolic and thrombotic events (ROR = 6.66, IC = 2.74), cardiac failure (ROR = 3.86, IC = 1.95), and ischemic heart disease (ROR = 3.37, IC = 1.75) indicated positive signals in HIF-PHIs. The median time to onset (TTO) of hypertension for HIF-PHIs was noted to be the earliest at 15.50 days. HIF-PHIs are related to multiple cardiovascular toxicities. Although disproportionality analysis is a hypothesis-driven method, improving the surveillance of these toxicities related to HIF-PHIs used in managing renal anemia is still crucial.
- 4 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e206-e208
Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications
- 4 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , e206-e208
Control compounds for drug-induced liver injury evaluation: Evidence from Database of Adverse Event Notifications
- 2 December 2024
- Published by Wiley in Liver International
- Vol. 45 (4)
Non‐Linear Trends in the Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) From 1990 to 2021
- 2 December 2024
- Published by Wiley in Liver International
- Vol. 45 (4)
Non‐Linear Trends in the Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) From 1990 to 2021
- 18 November 2024
- Published by Wiley in Liver International
- Vol. 45 (4)
Overall Mortality and Cardiovascular Mortality Associated With MAFLD +/ NAFLD− Versus MAFLD− / NAFLD +: A Secondary Analysis
- 18 November 2024
- Published by Wiley in Liver International
- Vol. 45 (4)
Overall Mortality and Cardiovascular Mortality Associated With MAFLD +/ NAFLD− Versus MAFLD− / NAFLD +: A Secondary Analysis
- Open Access
- 12 January 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-17
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Background: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of first-line and second/further-line treatments remain uncertain. Accordingly, our aim was to conduct a comprehensive evaluation of the efficacy and safety of these therapies through network meta-analysis.Methods: RCTs were identified by searching Pubmed, Embase, and major cancer conferences. The efficacy of interventions was assessed using the hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), while safety was indicated by the incidence of any grade adverse events (AEs), grade 3–5 AEs, AEs leading to treatment discontinuation, and AEs leading to death. Both time-variant HRs fractional polynomial models and time-invariant HRs Cox-proportional hazards models were considered for handling time-to-event data. Safety indicators were analyzed using Bayesian network meta-analysis. Additionally, subgroup analyses were conducted based on patient characteristics.Results: A total of 41 RCTs (first-line 17, second/further-lines 27) were included in the analysis. For first-line treatment, the addition of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy significantly improved therapeutic efficacy in terms of both PFS and OS, demonstrating the best performance across all mechanisms. Specifically, the combination of Abemaciclib and Letrozole demonstrated the most favorable performance in terms of PFS, while Ribociclib plus Fulvestrant yielded the best outcomes in OS. Incorporating the immune checkpoint inhibitor Avelumab into the regimen with CDK4/6 inhibitors and selective estrogen receptor degraders significantly enhanced both PFS and OS in second-line or later treatments. Regarding safety, endocrine monotherapy performed well. Regarding safety, endocrine monotherapy performed well. There is mounting evidence suggesting that most CDK4/6 inhibitors may demonstrate poorer performance with respect to hematologic AEs. However, additional evidence is required to further substantiate these findings.Conclusions: CDK4/6 inhibitors, combined with endocrine therapy, are pivotal in first-line treatment due to their superior efficacy and manageable AEs. For second/further-line treatment, adding immune checkpoint inhibitors to CDK4/6 inhibitors plus endocrine therapy may produce promising results. However, to reduce the results’ uncertainty, further trials comparing these novel treatments are warranted.Trial registration: Registration number: PROSPERO (CRD42022377431).
- 12 January 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-17
Open AccessA network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer
Background: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of first-line and second/further-line treatments remain uncertain. Accordingly, our aim was to conduct a comprehensive evaluation of the efficacy and safety of these therapies through network meta-analysis.Methods: RCTs were identified by searching Pubmed, Embase, and major cancer conferences. The efficacy of interventions was assessed using the hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), while safety was indicated by the incidence of any grade adverse events (AEs), grade 3–5 AEs, AEs leading to treatment discontinuation, and AEs leading to death. Both time-variant HRs fractional polynomial models and time-invariant HRs Cox-proportional hazards models were considered for handling time-to-event data. Safety indicators were analyzed using Bayesian network meta-analysis. Additionally, subgroup analyses were conducted based on patient characteristics.Results: A total of 41 RCTs (first-line 17, second/further-lines 27) were included in the analysis. For first-line treatment, the addition of Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy significantly improved therapeutic efficacy in terms of both PFS and OS, demonstrating the best performance across all mechanisms. Specifically, the combination of Abemaciclib and Letrozole demonstrated the most favorable performance in terms of PFS, while Ribociclib plus Fulvestrant yielded the best outcomes in OS. Incorporating the immune checkpoint inhibitor Avelumab into the regimen with CDK4/6 inhibitors and selective estrogen receptor degraders significantly enhanced both PFS and OS in second-line or later treatments. Regarding safety, endocrine monotherapy performed well. Regarding safety, endocrine monotherapy performed well. There is mounting evidence suggesting that most CDK4/6 inhibitors may demonstrate poorer performance with respect to hematologic AEs. However, additional evidence is required to further substantiate these findings.Conclusions: CDK4/6 inhibitors, combined with endocrine therapy, are pivotal in first-line treatment due to their superior efficacy and manageable AEs. For second/further-line treatment, adding immune checkpoint inhibitors to CDK4/6 inhibitors plus endocrine therapy may produce promising results. However, to reduce the results’ uncertainty, further trials comparing these novel treatments are warranted.Trial registration: Registration number: PROSPERO (CRD42022377431).